相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion
Kevin C. Conlon et al.
CLINICAL CANCER RESEARCH (2019)
Engineering antigen-specific NK cell lines against the melanoma-associated antigen tyrosinase via TCR gene transfer
Ayhan Parlar et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2019)
Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells
Takahiro Kamiya et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel 1L2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors
Salah-Eddine Bentebibel et al.
CANCER DISCOVERY (2019)
Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity
Laurent Gauthier et al.
CELL (2019)
Targeting NKG2A to elucidate natural killer cell ontogenesis and to develop novel immune-therapeutic strategies in cancer therapy
Elisa Zaghi et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2019)
De novo design of potent and selective mimics of IL-2 and IL-15
Daniel-Adriano Silva et al.
NATURE (2019)
The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex
Caroline Jochems et al.
ONCOIMMUNOLOGY (2019)
NK cells specifically TCR-dressed to kill cancer cells
Nadia Mensali et al.
EBIOMEDICINE (2019)
Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity
E. Liu et al.
LEUKEMIA (2018)
First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
Rizwan Romee et al.
BLOOD (2018)
Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity
Ye Li et al.
CELL STEM CELL (2018)
Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML
Andreas T. Bjorklund et al.
CLINICAL CANCER RESEARCH (2018)
Phase I clinical trial of adoptive transfer of expanded natural killer cells in combination with IgG1 antibody in patients with gastric or colorectal cancer
Takeshi Ishikawa et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
NKG2D Immunoligand rG7S-MICA Enhances NK Cell-mediated Immunosurveillance in Colorectal Carcinoma
Tong Wang et al.
JOURNAL OF IMMUNOTHERAPY (2018)
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial
John M. Wrangle et al.
LANCET ONCOLOGY (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies
Norbert Vey et al.
Oncotarget (2018)
Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37
Dhifaf Sarhan et al.
CANCER IMMUNOLOGY RESEARCH (2018)
A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma
Wing Keung Chan et al.
CANCER IMMUNOLOGY RESEARCH (2018)
The Role of CXC Chemokine Receptors 1-4 on Immune Cells in the Tumor Microenvironment
Katharina Helene Susek et al.
FRONTIERS IN IMMUNOLOGY (2018)
NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines
Nadine van Montfoort et al.
CELL (2018)
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
Pascale Andre et al.
CELL (2018)
Tumor Microenvironment-Induced Immunometabolic Reprogramming of Natural Killer Cells
Andrea M. Chambers et al.
FRONTIERS IN IMMUNOLOGY (2018)
Natural killer cells and other innate lymphoid cells in cancer
Laura Chiossone et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect
Martin Felices et al.
JCI INSIGHT (2018)
161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS
Dhifaf Sarha et al.
BLOOD ADVANCES (2018)
An Fc-optimized CD133 antibody for induction of NK cell reactivity against myeloid leukemia
S. P. Koerner et al.
LEUKEMIA (2017)
LAG3 (CD223) as a cancer immunotherapy target
Lawrence P. Andrews et al.
IMMUNOLOGICAL REVIEWS (2017)
Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization
Silvia Pesce et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
IL-18/IL-15/IL-12 synergy induces elevated and prolonged IFN-γ production by ex vivo expanded NK cells which is not due to enhanced STAT4 activation
Evan Lusty et al.
MOLECULAR IMMUNOLOGY (2017)
IL-1R8 is a checkpoint in NK cells regulating anti-tumour and anti-viral activity
Martina Molgora et al.
NATURE (2017)
Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells
Thorsten Gantke et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2017)
The histone deacetylase inhibitor SAHA simultaneously reactivates HIV-1 from latency and up-regulates NKG2D ligands sensitizing for natural killer cell cytotoxicity
Maria Giovanna Desimio et al.
VIROLOGY (2017)
Loss of Fas expression and high expression of HLA-E promoting the immune escape of early colorectal cancer cells
Renxiang Huang et al.
ONCOLOGY LETTERS (2017)
IL-21-mediated reversal of NK cell exhaustion facilitates anti-tumour immunity in MHC class I-deficient tumours
Hyungseok Seo et al.
NATURE COMMUNICATIONS (2017)
Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis
Eva M. Putz et al.
ONCOIMMUNOLOGY (2017)
IL-12, IL-15, and IL-18 pre-activated NK cells target resistant T cell acute lymphoblastic leukemia and delay leukemia development in vivo
Margherita Boieri et al.
ONCOIMMUNOLOGY (2017)
Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma
Veronika Kremer et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-2, and Haploidentical Natural Killer Cells
Aimee C. Talleur et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells
Loredana Ruggeri et al.
HAEMATOLOGICA (2016)
Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells
Loredana Ruggeri et al.
HAEMATOLOGICA (2016)
Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models
Peter R. Rhode et al.
CANCER IMMUNOLOGY RESEARCH (2016)
IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells
Yumeng Mao et al.
BLOOD (2016)
Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells
Dhifaf Sarhan et al.
CANCER RESEARCH (2016)
Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy
Stephen J. Blake et al.
CLINICAL CANCER RESEARCH (2016)
NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
Deborah H. Charych et al.
CLINICAL CANCER RESEARCH (2016)
IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function
Daniel A. Vallera et al.
CLINICAL CANCER RESEARCH (2016)
Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma
Mattias Carlsten et al.
CLINICAL CANCER RESEARCH (2016)
Enhanced ADCC and NK Cell Activation of an Anticarcinoma Bispecific Antibody by Genetic Insertion of a Modified IL-15 Cross-linker
Joerg U. Schmohl et al.
MOLECULAR THERAPY (2016)
CIS is a potent checkpoint in NK cell-mediated tumor immunity
Rebecca B. Delconte et al.
NATURE IMMUNOLOGY (2016)
TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway
Sebastien Viel et al.
SCIENCE SIGNALING (2016)
TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway
Sebastien Viel et al.
SCIENCE SIGNALING (2016)
Phase I Study of Random Healthy Donor-Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors
Yaewon Yang et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia
Emily M. McWilliams et al.
ONCOIMMUNOLOGY (2016)
NK cells and cancer: you can teach innate cells new tricks
Maelig G. Morvan et al.
NATURE REVIEWS CANCER (2016)
Inhibitory receptors as targets for cancer immunotherapy
Meghan E. Turnis et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2015)
The Clinical Significance of Abnormal Tim-3 Expression on NK Cells from Patients with Gastric Cancer
Zhenxin Wang et al.
IMMUNOLOGICAL INVESTIGATIONS (2015)
Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma
Liyun Xu et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2015)
Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer
Kevin C. Conlon et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
B7H6-Specific Bispecific T Cell Engagers Lead to Tumor Elimination and Host Antitumor Immunity
Ming-Ru Wu et al.
JOURNAL OF IMMUNOLOGY (2015)
Expression of immune checkpoint molecules of T cell immunoglobulin and mucin protein 3/galectin-9 for NK cell suppression in human gastrointestinal stromal tumors
Hideo Komita et al.
ONCOLOGY REPORTS (2015)
The Shared and Contrasting Roles of IL2 and IL15 in the Life and Death of Normal and Neoplastic Lymphocytes: Implications for Cancer Therapy
Thomas A. Waldmann
CANCER IMMUNOLOGY RESEARCH (2015)
IL-15-PI3K-AKT-mTOR: a critical pathway in the life journey of natural killer cells
Alaa Kassim Ali et al.
FRONTIERS IN IMMUNOLOGY (2015)
Critical role of tumor microenvironment in shaping NK cell functions: implication of hypoxic stress
Meriem Hasmim et al.
FRONTIERS IN IMMUNOLOGY (2015)
Therapeutic potential and challenges of natural killer cells in treatment of solid tumors
Andrea Gras Navarro et al.
FRONTIERS IN IMMUNOLOGY (2015)
CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo
Erik Wennerberg et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide
Inger S. Nijhof et al.
HAEMATOLOGICA (2015)
Targeting CD20+ Aggressive B-cell Non-Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice
Yaya Chu et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies
Holbrook E. Kohrt et al.
BLOOD (2014)
Antibody Fc engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells
Gabrielle Romain et al.
BLOOD (2014)
CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets
Michelle K. Gleason et al.
BLOOD (2014)
Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein
Veronika Bachanova et al.
BLOOD (2014)
Valproic acid sensitizes pancreatic cancer cells to natural killer cell-mediated lysis by upregulating MICA and MICB via the PI3K/Akt signaling pathway
Pengfei Shi et al.
BMC CANCER (2014)
Inhibition of Tumor-Derived Prostaglandin-E2 Blocks the Induction of Myeloid-Derived Suppressor Cells and Recovers Natural Killer Cell Activity
Yumeng Mao et al.
CLINICAL CANCER RESEARCH (2014)
Effect of tumor cells and tumor microenvironment on NK-cell function
Massimo Vitale et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2014)
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma
Neha Korde et al.
HAEMATOLOGICA (2014)
The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma
Achim Rothe et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
IL-2: The First Effective Immunotherapy for Human Cancer
Steven A. Rosenberg
JOURNAL OF IMMUNOLOGY (2014)
The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions
Christopher J. Chan et al.
NATURE IMMUNOLOGY (2014)
Therapeutic vaccines for cancer: an overview of clinical trials
Ignacio Melero et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade
Ines Pires da Silva et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity
Henri-Alexandre Michaud et al.
ONCOIMMUNOLOGY (2014)
A novel inhibitor of proteasome deubiquitinating activity renders tumor cells sensitive to TRAIL-mediated apoptosis by natural killer cells and T cells
Dhifaf Sarhan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors
Sylvie Rusakiewicz et al.
CANCER RESEARCH (2013)
Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16 x 33 Bispecific Killer Cell Engager and ADAM17 Inhibition
Andres Wiernik et al.
CLINICAL CANCER RESEARCH (2013)
The Interleukin-1 Family: Back to the Future
Cecilia Garlanda et al.
IMMUNITY (2013)
Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling
Erik Wennerberg et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency
Marie Vincent et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Rescue of Impaired NK Cell Activity in Hodgkin Lymphoma With Bispecific Antibodies In Vitro and in Patients
Katrin S. Reiners et al.
MOLECULAR THERAPY (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission
Norbert Vey et al.
BLOOD (2012)
A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma
Don M. Benson et al.
BLOOD (2012)
Cytokine activation induces human memory-like NK cells
Rizwan Romee et al.
BLOOD (2012)
A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies
Noriko Shimasaki et al.
CYTOTHERAPY (2012)
Immunocytokines: a novel class of potent armed antibodies
Nadine Pasche et al.
DRUG DISCOVERY TODAY (2012)
Construction and humanization of a functional bispecific EGFR CD16 diabody using a refolding system
Ryutaro Asano et al.
FEBS JOURNAL (2012)
Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'
Aron M. Levin et al.
NATURE (2012)
Targeting natural killer cells and natural killer T cells in cancer
Eric Vivier et al.
NATURE REVIEWS IMMUNOLOGY (2012)
Adoptive immunotherapy for cancer: harnessing the T cell response
Nicholas P. Restifo et al.
NATURE REVIEWS IMMUNOLOGY (2012)
Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients
Antonio Curti et al.
BLOOD (2011)
IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect
Don M. Benson et al.
BLOOD (2011)
Heterodimeric bispecific antibody-derivatives against CD19 and CD16 induce effective antibody-dependent cellular cytotoxicity against B-lymphoid tumor cells
Christian Kellner et al.
CANCER LETTERS (2011)
Human Breast Tumor Cells Induce Self-Tolerance Mechanisms to Avoid NKG2D-Mediated and DNAM-Mediated NK Cell Recognition
Emilie Mamessier et al.
CANCER RESEARCH (2011)
Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression
Maria R. Parkhurst et al.
CLINICAL CANCER RESEARCH (2011)
A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer
Melissa A. Geller et al.
CYTOTHERAPY (2011)
Bortezomib Treatment to Potentiate the Anti-tumor Immunity of Ex-vivo Expanded Adoptively Infused Autologous Natural Killer Cells
Andreas Lundqvist et al.
JOURNAL OF CANCER (2011)
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
Don M. Benson et al.
BLOOD (2010)
Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method
L. Li et al.
CANCER GENE THERAPY (2010)
A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer
Eleni G. Iliopoulou et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells
Francois Romagne et al.
BLOOD (2009)
Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells
Andreas Lundqvist et al.
BLOOD (2009)
Permanent silencing of NKG2A expression for cell-based therapeutics
Constanca Figueiredo et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2009)
Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo
Caroline Sola et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
New insights into the regulation of T cells by γc family cytokines
Yrina Rochman et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells
Mareike Schmudde et al.
CANCER LETTERS (2008)
Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition
William H. D. Hallett et al.
JOURNAL OF IMMUNOLOGY (2008)
The role of NK cell recognition of nectin and nectin-like proteins in tumor immunosurveillance
Anja Fuchs et al.
SEMINARS IN CANCER BIOLOGY (2006)
Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: A novel method to potentiate natural killer cell tumor cytotoxicity
Andreas Lundqvist et al.
CANCER RESEARCH (2006)
Engineered antibody Fc variants with enhanced effector function
GA Lazar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo
EP von Strandmann et al.
BLOOD (2006)
Influence of variable N-glycosylation on the cytolytic potential of chimeric CD19 antibodies
K Barbin et al.
JOURNAL OF IMMUNOTHERAPY (2006)
Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B
S Skov et al.
CANCER RESEARCH (2005)
CD4+ CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-β-dependent manner
F Ghiringhelli et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Licensing of natural killer cells by host major histocompatibility complex class I molecules
S Kim et al.
NATURE (2005)
Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D Ligands by the histone deacetylase inhibitor sodium valproate
S Armeanu et al.
CANCER RESEARCH (2005)
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer
JS Miller et al.
BLOOD (2005)
The cell biology of the human natural killer cell CD94/NKG2A inhibitory receptor
F Borrego et al.
MOLECULAR IMMUNOLOGY (2005)
A recombinant bispecific single-chain Fv antibody against HLA class II and FcγRIII (CD16) triggers effective lysis of lymphoma cells
J Bruenke et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
A trivalent anti-erbB2/anti-CD16 bispecific antibody retargeting NK cells against human breast cancer cells
ZG Xie et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial
LJ Burns et al.
BONE MARROW TRANSPLANTATION (2003)
IL-15 promotes the survival of naive and memory phenotype CD8+ T cells
M Berard et al.
JOURNAL OF IMMUNOLOGY (2003)
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
L Ruggeri et al.
SCIENCE (2002)
Expression of GnTIII in a recombinant anti-CD20 CHO production cell line:: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FcγRIII
J Davies et al.
BIOTECHNOLOGY AND BIOENGINEERING (2001)
分享论文
